Oxford Pharmascience saw revenues jump in the first half after it signed a sales deal with one of Brazil's largest pharmaceutical companies.
Revenues came in at £341,000, up from £20,000 the year before, with sales to Brazil's Ach making up the lions share.
The pharmaceutical technology company cut its pre-tax loss to £399,000, from £501,000 in the first half of 2011, with loss per share coming in at 0.07p.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Chairman David Norwood said 2011 was a breakthrough year for the company having changed its focus to the higher value pharmaceutical market.
"The commencement of sales to Ach, one of Brazil's largest pharmaceutical companies and the launch of its OXP zero taste masking technology left [the company] well placed going into this year," he said.
-
Lioness legend Jill Scott: “I want to be a role model to get women into investing”Lioness Jill Scott says she wants to be a role model for women to start investing, in the same way she inspired girls to play football. She also questions why topics like investing, tax and mortgages aren’t taught in schools
-
UK dividends payments drop 1.4% with investors raking in £1 billion less than last yearInvestors in UK firms were paid a total of £24.6 billion in dividends in the third quarter of 2025, down 1.4% from the same period last year as UK companies come under pressure.
